Last C$3.58 CAD
Change Today +0.015 / 0.42%
Volume 391.5K
CRH On Other Exchanges
Symbol
Exchange
Toronto
As of 3:59 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

crh medical corp (CRH) Snapshot

Open
C$3.58
Previous Close
C$3.56
Day High
C$3.73
Day Low
C$3.55
52 Week High
02/25/15 - C$4.15
52 Week Low
05/20/14 - C$0.61
Market Cap
217.7M
Average Volume 10 Days
1.1M
EPS TTM
C$0.03
Shares Outstanding
60.9M
EX-Date
--
P/E TM
95.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for CRH MEDICAL CORP (CRH)

Related News

No related news articles were found.

crh medical corp (CRH) Related Businessweek News

No Related Businessweek News Found

crh medical corp (CRH) Details

CRH Medical Corporation, a medical company, provides products and services to physicians for the treatment of gastrointestinal diseases in the United States. The company offers the CRH O’Regan System, a single use, disposable, and hemorrhoid banding technology for treating hemorrhoid grades I–IV. It distributes the CRH O’Regan System, treatment protocols, and operational and marketing expertise as a turnkey package directly to its partner physicians. The company also offers anesthesia services. The company was formerly known as Medsurge Medical Products Corp. and changed its name to CRH Medical Corporation in April 2006. CRH Medical Corporation was founded in 2000 and is headquartered in Vancouver, Canada.

Founded in 2000

crh medical corp (CRH) Top Compensated Officers

Chief Executive Officer, President and Non-In...
Total Annual Compensation: $287.2K
Chief Financial Officer and Corporate Secreta...
Total Annual Compensation: $224.4K
Compensation as of Fiscal Year 2013.

crh medical corp (CRH) Key Developments

CRH Medical Corporation Announces Audited Earnings Results for the Year Ended December 31, 2014

CRH Medical Corporation announced audited earnings results for the year ended December 31, 2014. For the year, the company announced total operating EBITDA of USD 4,696,095 compared to USD 2,116,563 for the same period a year ago. Operating income was USD 2,977,893 compared to USD 1,799,795 for the same period a year ago. Total revenue was USD 11,984,170 compared to USD 7,682,628 for the same period a year ago. The 12% increase in product sales is the result of the continuing successful execution of the company's direct to physician program that provides physicians the ability to purchase the company’s hemorrhoid banding technology, treatment protocols, marketing and operational experience. Operating EBITDA was primarily a reflection of Gastroenterology Anesthesia Associates, LLC's contribution during the month of December 2014, offset by net increases in product and corporate operating expenses. For the year ended December 31, 2014, the company recorded net income of USD 1,498,153 (USD 0.031 basic and USD 0.030 diluted income per share) compared to a net income of USD 2,492,646 (USD 0.051 basic and diluted income per share) for the year ended December 31, 2013. The decrease in net income year over year is largely a reflection of the net finance expense recorded in 2014 and other expenses related to the acquisition of Gastroenterology Anesthesia Associates, LLC.

Lafarge And Holcim Receives Bid Approach For Its Assets

Lafarge S.A. (ENXTPA:LG) and Holcim Ltd. (SWX:HOLN) are planning to sell €6 billion worth of assets. The three groups expected to hand in binding bids by a mid January 2014 are CRH Medical Corporation (TSX:CRH), The Blackstone Group L.P. (NYSE:BX), Cinven and Canada Pension Plan Investment Board, a team consisting of CVC Limited (ASX:CVC) and sovereign wealth funds Abu Dhabi Investment Authority and GIC Pte. Ltd. Lafarge and Holcim will sell overlapping assets worth 12% of combined revenues to secure European Union antitrust approval for their merger earlier this week. Holcim said in November 2014 that it has more than 60 tentative bids from industry interests and private equity firms for the assets. Italcementi SpA (BIT:IT) and Sabanci Cimento Group are interested only in some of the assets, the sources said. "The seller is likely to prefer a sale of the complete bundle to one buyer, as a divestment in pieces bears the risk of being left with unattractive, unsellable parts," one of the sources said. HeidelbergCement AG (DB:HEI) and CEMEX, S.A.B. de C.V. (NYSE:CX) said that they are not interested in the assets. BC Partners, Advent International Corporation and Temasek Capital Management Pte Ltd as well as Bain Capital Ltd and Onex Corporation (TSX:OCX) have also shelved their preparatory work, sources familiar with the deal said. A Lafarge spokeswoman said: "The sales process is progressing well. Holcim and Lafarge have established a clear process for their divestments and we expect final bids early 2015." Onex, Sabanci and GIC were not immediately available for comment. The other companies and investors declined to comment.

CRH Medical Corporation, Gastroenterology Anesthesia Associates, LLC - M&A Call

To discuss the acquisition of Gastroenterology Anesthesia Associates, LLC

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRH:CN C$3.58 CAD +0.015

CRH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CRH.
View Industry Companies
 

Industry Analysis

CRH

Industry Average

Valuation CRH Industry Range
Price/Earnings 95.0x
Price/Sales 11.7x
Price/Book 9.3x
Price/Cash Flow 116.1x
TEV/Sales 10.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CRH MEDICAL CORP, please visit www.crhmedcorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.